Renal cell carcinoma-associated antigen G250 encodes a naturally processed epitope presented by human leukocyte antigen-DR molecules to CD4(+) T lymphocytes.
We previously identified an HLA-A2.1-restricted epitope within the RCC-associated antigen G250 that is recognized by CTLs. Using DCs of healthy individuals, which were loaded with overlapping 20 mer G250-derived peptides, we here report the induction of CD4(+) T cells that recognize the G250 peptide of amino acids 249-268. Moreover, naturally processed G250 protein is readily recognized by these G250-specific CD4(+) T cells in the context of HLA-DR molecules. Interestingly, peptide G250:249-268 overlaps the previously identified HLA-A2.1-restricted G250 epitope recognized by CTLs. These data and the high prevalence of G250 in RCC patients make peptide G250:249-268 a potential target in peptide-based vaccines to induce both CD4(+) and CD8(+) T-cell responses in patients.
Tumor Immunology Laboratory, University Medical Center Nijmegen St. Radboud, Nijmegen, The Netherlands.
Joost L M
JL
Vissers
I Jolanda M
IJ
De Vries
Linda P H
LP
Engelen
Nicole M
NM
Scharenborg
Janneke
J
Molkenboer
Carl G
CG
Figdor
Egbert
E
Oosterwijk
Gosse J
GJ
Adema
D000595:Amino Acid Sequence; D000951:Antigens, Neoplasm / Q000276:immunology*; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology*; D002292:Carcinoma, Renal Cell / Q000276:immunology*; D000939:Epitopes; D006684:HLA-DR Antigens / Q000276:immunology*; D006801:Humans; D010455:Peptides / Q000276:immunology
D000951:Antigens, Neoplasm; D000939:Epitopes; D006684:HLA-DR Antigens; D010455:Peptides; C400566:antigen G250